Project Grant R01HL177000
Award Date
4/1/25
Completion Date
1/31/29
Dollars Obligated
$583K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This federal Project Grant award of $755,228.26 from the National Heart, Lung, and Blood Institute (NHLBI), Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in modulating inflammation and promoting recovery from pneumonia. The award, spanning from July 2024 to June 2027, will be provided to the University of Iowa to conduct this research. The project aims to elucidate how...
This federal Project Grant award of $880,735 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the mechanisms by which cell lysis induces leukotriene synthesis, which activates type-2 immunity in the lung. The research aims to identify alveolar macrophages as a key source of leukotriene C4 (LTC4) and study how its synthesis is regulated, as well as examine the contributions of LTC4 and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research grant program (CFDA 93.837), provides $1,875,540.00 to the University of Illinois to investigate the role of perivascular macrophages in promoting endothelial cell regeneration and vascular repair following acute lung injury and acute respiratory distress syndrome (ARDS). The researchers will use intravital microscopy imaging to observe the dynamic...
This $774,585 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of inflammatory fibroblasts in the development of pulmonary fibrosis. The project aims to: 1) characterize the emergence and persistence of inflammatory fibroblasts in different models of lung injury and fibrosis, 2) determine the mechanisms driving the transition of inflammatory...
This $480,990 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of aerocytes, a specialized capillary endothelial cell population, in alveolar epithelial regeneration following acute lung injury. The research aims to investigate how aerocyte-derived signaling, particularly the R-spondin3 molecule, guides the regenerative remodeling of alveolar epithelium and establishes a...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $777,048 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant will fund research focused on enhancing host resilience against acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) through the induction of myeloid-epithelial gap junctional channels. The research aims to evaluate the extent to which...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research on the regulation of primary and secondary alveologenesis by FGF signaling pathways. The $740,317 award to The Washington University, a prominent private research institution based in St. Louis, Missouri, runs from January 29, 2025 to November 30, 2028.
The research aims to identify the cellular mechanisms by which the FGF...
The Project Grant award R01HL177904, totaling $773,446.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research at The Washington University in University City, Missouri to investigate the role of the matricellular protein thrombospondin-1 (TSP1) in stabilizing the provisional extracellular matrix and regulating cellular processes during acute lung injury (ALI) and the acute...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $186,408 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Washington to conduct research on targeting cluster of differentiation 14 (CD14) as a potential therapeutic approach for acute respiratory distress syndrome (ARDS). The five-year grant, running from September 1, 2024 to August 31, 2029, aims to: 1) analyze the effects of the CD14-blocking monoclonal antibody IC14 on blood leukocyte gene...
This $762,405.80 federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of South Alabama (USA). The award aims to investigate the mechanisms by which cell-free hemoglobin and oxidized low-density lipoprotein contribute to microvascular hyperpermeability and lung injury during sepsis. Specifically, the project will examine how the lectin-like oxidized LDL receptor 1...